Diabetic retinopathy is a severe, sight-damaging complication of diabetes. Early diagnosis minimises the risk of fatal complications and sight loss. For this reason, everyone with diabetes should undergo an eye examination every year. More than 40% of patients do not undergo regular examination, however. Aireen® allows for fast, precise, pain-free and accessible eye screening for patients with diabetes.

In just 60 seconds, Aireen® assesses a retina image with high precision.

• Secure - High sensitivity and very low on false positives
• Comfortable - Result in less than 60 seconds
• Proven - through clinical trials

Since May 2023 Aireen® diabetic retinopathy screening has been certified as class IIb EU-MDR medical device.

Age-related macular degeneration (AMD) is a disease of the retina and is the most common cause of blindness amongst older people, occurring in over 8% of the population over 50.

Aireen AMD screening assesses an image of the retina in 60 seconds, and confirms or rejects the presence of disease symptoms.

• Secure - High sensitivity and very low on false positives
• Comfortable - Result in less than 60 seconds
• Proven - through clinical trials

Since May 2024 Aireen® age-related macular degeneration screening from fundus images has been certified as class IIb EU-MDR medical device (CE 2265).

Glaucoma is a disease which results in progressive damage to the optic nerve. Left untreated, glaucoma can result in blindness.

Across the world, around 1.5 to 2% of the population over 40 suffer from glaucoma-related optic nerve damage.

Planned Aireen glaucoma screening assesses an image of the retina in 30 seconds, and with high precision detects changes in the image which indicate the suspected presence of the disease.

This project focuses on data analysis of patients with high blood pressure and automatic assessment of vascular and retinal damage.

The damage will be classified into four grades:

1. Hypertensive angiopathy,

2. Hypertensive angiosclerosis,

3. Hypertensive retinopathy, and

4. Hypertensive neuroretinopathy.

Automating this assessment, which is routinely performed by ophthalmologists, will greatly facilitate the work not only of them, but also of cardiologists, internists and general practitioners.

In the next phase of the project, we will focus on a detailed analysis of biomarkers and the evaluation of the risk of other vascular diseases, such as stroke and ischemic heart disease, through regular photographs of the retina of patients with these problems.